Mirati - oncology?

Quote
anonymous said:
LOL. Nice try! You clearly have no clue why Phil was let go. Keep guessing though....
You must be in SC since you have such strong opinions on the CMC team.
And yes, your post was racist and uncalled for.
Click to expand...

It's not racist to name an obvious leadership deficit - which is the inability to effectively communicate orally or in writing using the global language of science and business. If you imagine that deficit is a racial characteristic, then the perceived racism is coming from you.
 












anonymous said:
Are we bought yet?
Employees are disillusioned and disengaged with all the equity being under water. Mass exodus coming after the approval and launch The only hope is getting bought.
Click to expand...

Meek’s only hope is that there is someone out there who’s as inept at business development and company valuation as he is. Google Ipsen and Clementia.
 












anonymousw said:
They’re delusional. The company is still overvalued by at least 50-60%.



STAT: Who’s going to pay billions for Mirati?


Mirati Therapeutics went from biotech obscurity to buyout-rumor ubiquity thanks to adagrasib, a promising cancer drug aimed at a biological target once considered undruggable. But it remains unclear whether the company, which is reportedly considering a sale, can fetch the multibillion-dollar offer its valuation implies.

The latest Mirati news comes from Bloomberg, which reported yesterdaythat the company has retained an adviser to consider potential takeovers and that big companies have been looking into it, with no deals imminent. The story sent Mirati’s share price, which has been cut nearly in half over the past year, up about 15%.

The problem for Mirati is timing. The FDA is scheduled to make a final decision on adagrasib next month, and while the drug’s approval is not in doubt, it remains unclear whether its label will be more restrictive than the one for Lumakras, an Amgen medicine aimed at the same so-called undruggable target. Beyond that, key data on adagrasib’s benefits for earlier stages of cancer are still on the horizon, making it unclear whether any potential suitor would be willing to pay in excess of $5 billion for the company in the presence of so many unknowns.
Click to expand...

Nice plan to try and dump the company before the CRL comes through from FDA or the shitty label becomes known. Too bad it won’t work.
 






anonymous said:
I agree and support these statements.
bring female leadership. No more boys club period. Uncomfortable environment in Techops. They treat us like we are pawns in their “cmc playbooks” or whatever it’s called. So many presentations of how to do our job then actually letting us do our job that we know how to do …. We are scientists for a reason! Worst decision is putting bill in charge. C suite need to fix department and bring in new people now before more people leave soon…..
Click to expand...


I agree too!!!!! Bring a women in for head of department
Hahaha LOL the “playbook” ran by “head of cmc pM” Oh lord. Telling us how to do our job because he is part of that “un”-leadership team. What happen to the days when mirAti was all about science and research. That did exist before the department just crumbled with all the unnecessary FTes that are zero value added. Coming to Mirati and focusing on the science was fun before and now it’s daunting with a huge black cloud. Horrible feeling. No satisfaction here anymore.
& also we now have nonTechnical people attempting to represent us in cmc - referring to bills group (ext- manufacturing) Can it get any worse ??????
To a potential buyer: clean house if mirati isn’t going to do so!
 






13 days and counting!

If you can't get it done, we'll find someone who can
  • Dec. 01, 2022 is 552 days since Lumakras' approval on May 28, 2021
  • Nov. 10, 2022 SVP of Tech Ops departs
  • Oct. 28, 2021 CMO and COO removed



anonymous said:
I agree and support these statements.
bring female leadership. No more boys club period. Uncomfortable environment in Techops. They treat us like we are pawns in their “cmc playbooks” or whatever it’s called. So many presentations of how to do our job then actually letting us do our job that we know how to do …. We are scientists for a reason! Worst decision is putting bill in charge. C suite need to fix department and bring in new people now before more people leave soon…..
Click to expand...
 






anonymous said:
Pretty much. Very questionable hires at the 2L positions. Meathead in the west is a dope. No one cares that you played football at one of the worst teams, in the worst conferences, while at a terrible academic school….yet that is all he talks about. What a tool. You would have thought he won the Heisman, at Alabama, while winning a national championship, before going #1 in the NFL draft. Heck he even has it on his resume that he played DI football…took bag.
Click to expand...
 






anonymous said:
Pretty much. Very questionable hires at the 2L positions. Meathead in the west is a dope. No one cares that you played football at one of the worst teams, in the worst conferences, while at a terrible academic school….yet that is all he talks about. What a tool. You would have thought he won the Heisman, at Alabama, while winning a national championship, before going #1 in the NFL draft. Heck he even has it on his resume that he played DI football…took bag.
Click to expand...
 






5tnxq2
 
















































3 events to put the nail on Mirati’s coffin

Sapphire continue - low probability of success now

1L data- you see what happened to the stock. Massaged data and poor decision making.

what’s the bet on a competitive label? The data showed ada is toxic AF and I’m betting Mirati and CCO sprinkled its magic dust on top of it to royally fuck up any chance of a successful launch.

bye bye folks.
 


















Top Bottom
Back
Quote